Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 6 minute read Pharma Industry News Is Arcus Biosciences (RCUS) the dark horse of cancer immunotherapy after 26.7-month survival data? Arcus stock jumped after its domvanalimab-zimberelimab combo showed 26.7-month survival in gastric cancer. Find out what this means for its TIGIT pipeline. byVenkateshOctober 13, 2025